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Stimulation (SCS) provides pain relief and improves patients’ health. We 
assessed in a naturalistic context the cost-utility of SCS in FBSS patients 
unresponsive to conventional medical management (CMM). METHODS: We 
conducted an observational, multicenter, longitudinal prospective study in 
which a sample of patients assigned to receive SCS in addition to CMM was 
observed for 24 months after the intervention. We collected before and after 
undergoing SCS the following data: direct and indirect costs, adopting the 
National Health Service (NHS) and the societal perspectives, pain status, using 
the Numerical Rating Scale (NRS, scoring from 0 (no pain) to 10 (maximum pain)), 
and HRQoL, using the SF-36 and EQ-5D. Costs and benefits pre-SCS versus post-
SCS were compared to estimate the incremental cost-effectiveness and the cost-
utility ratios. The following results focus on the cost/QALY ratio. RESULTS: 
Eighty patients (40% male, mean age 58 years) were recruited. Significant 
improvements in pain intensity and HRQoL were reached after 6 months from 
SCS and maintained or further improved until the end of the observational 
period. In particular, after 24 months from SCS the mean NRS significantly 
decreased (p<0.01) from 7.6 to 5.1, and the mean EQ-5D-utility significantly 
(p<0.01) increased from 0.07 to 0.40. The ICUR was equal to 27,519€/QALY, 
according to the NHS perspective. The cost-utility acceptability curve shows that 
if decision makers’ willingness-to-pay per QALY was 45,000€, then SCS 
implantation would be cost effective in 97% and 99% of cases, according to the 
societal and NHS perspectives, respectively. CONCLUSIONS: In a 2-year 
observational period, SCS+CMM treatment of FBSS patients increases medical 
direct costs but allows to improve significantly patients’ clinical health and 
HRQoL, resulting in a cost/QALY ratio largely lower than the commonly accepted 
willingness-to-pay threshold.  
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OBJECTIVES: Under the standard methods of health technology assessment 
(HTA) incorporating economic evaluation, orphan drugs do not usually prove to 
be cost-effective. Adding their high cost, it meant that funding and patient 
access may be limited in the Brazilian Public Health System (SUS). Acromegaly is 
one example, with annual incidence of 3-4 cases/million and prevalence of 40-90 
cases/million. There is a new drug, pegvisomant, which presents a relative 
efficacy at a high cost. With the objective to identify the best 
pharmacoeconomics evidence for pegvisomant in acromegaly and to review the 
knowledgment transfer to support a rapid economic review of rare diseases 
under the perspective of SUS. METHODS: In the case of the rare disease 
acromegaly a search was conducted on February 10th, 2013 using \’cost\’/exp OR 
cost AND effectiveness AND (\’pegvisomant\’/exp OR pegvisomant) AND 
(\’acromegaly\’/exp OR acromegaly) in Medline (PubMed), EMBASE, Virtual Health 
Library (BVS), Center for Reviews and Dissemination (CRD), The Cochrane 
Library. RESULTS: Only the study “Clinical effectiveness and cost-effectiveness of 
pegvisomant for the treatment of acromegaly: a systematic review and economic 
evaluation” was identified and selected. The study was conducted in the UK, 
where health costs are different from the Brazilian structure RESULTS: The 
study´s evidence indicates that pegvisomant is not cost-effective to treat 
pacients with resistant agromegaly. In Brazil the cost of each dose in the public 
health system is about 25% more expensive than the UK, and so is the cost of 
labor. CONCLUSIONS: The need of economic assessment transferability as a tool 
to support the management of political decisions, especially to high cost 
technologies and rare diseases, are not set as priority in the research fostering 
agenda of the SUS  
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OBJECTIVES: Type I Gaucher disease (GD) is an autosomal recessive disorder 
caused by a deficiency in β-glucocerebrosidase enzyme, causing 
hepatosplenomegaly, anaemia, trombocitopenia, bone injuries and other 
complications. Intravenous enzyme replacement therapy (ERT) is the current 
standard of care, which has demonstrated in several studies its efficacy in  
the prevention and amelioration of progressive and systemic manifestations. 
Velaglucerase alpha is a glycoprotein with the same amino acid sequence as the 
human enzyme β-glucocerebrosidase. The aim of this study is to assess the cost-
effectiveness of velaglucerase alpha versus imiglucerase for the treatment  
of type 1 GD from the perspective of the Spanish National Healthcare System 
(NHS). METHODS: A cost-utility analysis was performed using a semi-Markov 
model that embedded one decision tree for the initial treatment during two 
years and a Markov health state structure after the response to the second year 
receiving ERT, from the NHS perspective. The Markov framework was structured 
around six health states: asymptomatic, mild, moderate, severe, splenectomy 
and death and used annual cycles with a time horizon of 39 years. Model 
structure was validated by a panel of GD experts. Efficacy data were obtained 
from the HGT-GCB-039 study. Resources consumption was based on expert 
opinion. Outcomes were quality-adjusted life years (QALY) and costs (€ in 2011). 
Threshold sensitivity analysis was conducted to determine cost-neutrality 
between strategies. RESULTS: Both strategies provided a mean gained of 25.55 
QALYs. The average cost per patient for velaglucerase alpha was €7,265,332 
compared to €7,327,966 for imiglucerase. The difference in costs was mainly due 
to the difference in administration costs. The threshold sensitivity analysis 
showed that velaglucerase alpha will reach cost-neutrality even with a higher 
unit price. CONCLUSIONS: Velaglucerase alpha is a cost-saving option for the 
treatment of type 1 GD in the Spanish setting, providing annual savings 
compared with imiglucerase. (This study was supported by Shire 
Pharmaceuticals Iberica)  
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OBJECTIVES: The purpose of this study was to conduct an economic analysis  
of clinical effectiveness of antiviral drugs in monotherapy (entecavir, 
lamivudine, telbivudine, tenofovir, peginterferon alfa-2a) compared with  
no specific treatment for patients with chronic hepatitis B in Russia. METHODS: 
Clinical-economic study was carried out with the Markov model.The duration of 
one cycle-1 year,the duration of antiviral treatment-5 years.As a measure  
of utility QALY were used. Due to the absence of Russian studies, a multinational 
study from 2008 was used. RESULTS: Total cost of one year of treatment  
of chronic hepatitis B were: lamivudine-35732.97 rubles, for entecavir-96104.00 
rubles for tenofovir-103279.55,for telbivudine-116933.75 for peginterferon-alfa-
2a-502238.40 rubles. The lowest cost-utility ratio (CUR) was for lamivudine-
91159.54 rubles/QALY. The highest CUR is for pegylated interferon alfa-2a and 
then tenofovir/entecavir-183263.00 rubles/QALY and 176936.58 rubles/QALY, 
respectively. More cost-effective treatment is to start with the third- 
line drugs-entecavir/tenofovir. The study showed that the use of 
entecavir,lamivudine,tenofovir is clinically and economically more effective than 
using no specific antiviral therapy.The CURs for these tactics is lower than that 
for the natural course of the disease.More effective from a clinical and economic 
point of view, for the treatment of chronic hepatitis B is to use as single one  
of these:entecavir/tenofovir/lamivudine. CONCLUSIONS: The quality of life  
of patients with chronic hepatitis B without the specific treatment will be lower 
than that with the antiviral drugs,since without the treatment increases the  
rate of formation of severe fibrosis in the liver, there is a quicker outcome to 
cirrhosis and other complications.Lowest CUR is for lamivudine due to the low 
cost of it,but the high rate of resistance to lamivudine and the need to add  
additional third-generation drug may increase the cost.The highest  
CUR is with administering pegylated interferon-alfa-2a and then  
applying tenofovir/entecavir. It seems economically feasible to begin therapy 
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OBJECTIVES: Few studies have reported the impact of laparoscopic adjustable 
gastric banding (LAGB) on work productivity in obese patients. The objective of 
this HERO study analysis is to examine the effect of weight loss (WL) on work 
productivity (absenteeism, presenteeism, and productivity loss) and non-work 
activity impairment 1 year (yr) after laparoscopic placement of LAP-BAND AP® 
System. METHODS: HERO is a 5-yr registry of 1,106 obese patients from 29 
centers in the United States (US), Canada, Europe, and Australia who underwent 
LAGB. Our descriptive analysis included about 70% of subjects who provided 
complete baseline (BL) and 1 yr health related quality of life data based on Work 
Productivity and Activity Impairment questionnaire, a well validated instrument 
generating scores in absenteeism, presenteeism, work productivity loss and non-
work activity impairment. RESULTS: The mean age was 43.1 yrs and females 
constituted 79.3%. At BL, 59% worked full time and 10% worked part time. Mean 
(SD) baseline weight was 126.2 (24.14) kg. At 1 year, the average %WL was 16.9% 
(SD, 9.02). Baseline presenteeism was 4.5%, absenteeism 33.4%, work productivity 
3.8%, and non-work activity impairment was 51.2%. At 1 year, there was 
reduction in presenteeism to 2.8% (p<0.05), in absenteeism to 20% (p<0.05), in 
work productivity to 2.3% (p<0.05), and non-work activity impairment to 28% 
(p<0.05). There was a decreasing trend in presenteeism (23.4%, 20.4%, 18.2%, 
14.1%, p=0.01) and less non-work activity impairment (32.9%, 29.7%, 22.7%, 17.5%, 
p<0.001) as %WL increased from 0-10%, to >10-20%, to >20-30%, and to >30%. 
This decrease was not observed with absenteeism (1.9%, 3.8%, 2.5%, 1.7%, p=0.28) 
nor productivity loss (2.1%, 2.2%, 2.7%, 1.8%, p=0.74) as %WL increased. 
CONCLUSIONS: LAGB was associated with significant WL and improvement in 
work productivity and reduction in non-work activity impairment by 1 yr. 
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OBJECTIVES: To examine cost to society due to underemployment among adults 
or parents of children (aged<18 years) with hemophilia A or B. METHODS: Data 
were obtained from HUGS Va and Vb, two multi-center cohort studies of persons 
with hemophilia A and B, respectively, who received comprehensive care at 
Hemophilia Treatment Centers in the United States. Underemployment, based 
on participants’ self-report, is defined as being employed part-time or 
unemployed due to hemophilia. Cost to society includes annualized aggregate 
earnings and non-wage benefits lost due to underemployment. The average 
hourly compensation rate was assumed to be US$30.80 based on the employer 
costs for employees’ compensation from the Bureau of Labor Statistics (2012). 
Part-time work was assumed to be 20 hours/week. Sensitivity analysis was 
conducted to determine the variation of cost by varying part-time work hours 
from 10 to 30 hours/week. RESULTS: Of 474 patients (329 hemophilia A), 275 
(58%) had severe hemophilia, of which 211 (64%) and 64 (44%) had hemophilia A 
and B, respectively. The number of adults or parents of children working full-
time, part-time or unemployed was 214 (45%), 96 (20%) and 163 (34%), 
respectively. Among the latter two groups, 24 (25%) part-time participants and 49 
(30%) unemployed participants attributed their employment status to 
hemophilia. Adults or parents of children with severe disease were more likely to 
be underemployed than those with mild/moderate disease (p=0.0002). The 
proportion of underemployed parents of children (12%) was comparable to that 
of underemployed adult patients (19%). Among the HUGS population, the 
estimated annual cost of underemployment to society due to hemophilia was 
US$3.91 million (range: $3.52-$4.29 million when varying part-time hours 
worked). CONCLUSIONS: Hemophilia involves costly life-long therapy, affecting 
the employability of patients and/or their families and imposing significant 
financial burden on society. Looking at new ways to support patients and 
families is essential in hemophilia care.  
 





FACTORS PREDICTING MEDICATION PERSISTENCE AMONG PATIENTS 
INITIATING BUPRENORPHINE TRANSDERMAL SYSTEM  
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OBJECTIVES: Buprenorphine transdermal system therapy (BTDS) is indicated for 
the management of moderate to severe chronic pain when a continuous, 
around-the-clock opioid analgesic is needed for an extended period of time. This 
study assessed factors associated with medication persistence among patients 
initiating BTDS. METHODS: Patients aged >18 years initiating BTDS during 
January 1, 2011 - November 30, 2011 were identified in the IMS Private 
Practitioner Medical Claims database and IMS Pharmacy Claims database. The 
index date was defined as the first prescription of BTDS. Demographics, 
Charlson Comorbidity Index (CCI) and prior medication use were assessed in the 
pre-index 6-month period. Persistence was measured as the duration of BTDS 
prior to the first 28-day refill gap in the post-index 6-month period. Cox 
proportional hazards models were run to assess predictors of BTDS persistence 
controlling for demographics, CCI, and prior and 30-day concomitant drug use. 
RESULTS: The study included 10,457 patients newly treated with BTDS. Patients’ 
mean age was 55 years (±15); 30% were male and the mean CCI was 1 (±1.4). Prior 
to the index BTDS prescription 92%, 35% and 59% of the patients used opioids, 
NSAIDs and neuropathic pain agents, respectively. Multivariate regression 
analyses showed that patients with prior opioid and neuropathic pain agent use 
were 20% and 5% less likely to discontinue BTDS (p<0.05), respectively as 
compared to patients not using these agents. Patients with concomitant use of 
neuropathic pain agents were 15% less likely to discontinue therapy (p<0.01) as 
compared to patients without concomitant use of neuropathic pain agents. 
Sensitivity analyses with 30-day prior opioid use and including patients with ≥2 
claims of BTDS confirmed these findings. CONCLUSIONS: Prior and concomitant 
use of neuropathic pain agents and prior use of opioids were associated with 
significantly longer persistence among patients initiating BTDS. These data help 
to characterize the patient population treated with BTDS.  
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OBJECTIVES: Buprenorphine transdermal system (BTDS) is indicated for  
the management of moderate to severe chronic pain when a continuous, 
around-the-clock opioid analgesic is needed for an extended period of time. The 
purpose of this study was to assess medication persistence in patients on BTDS 
across varying dose strengths and in patients who had a dose change. 
METHODS: Patients aged >18 years initiating BTDS during 1/1/2011-11/30/2011 
were identified in the IMS Private Practitioner Medical Claims database and IMS 
Pharmacy Claims database. The index date was defined as the first prescription 
of BTDS. Medication persistence, dose change and final dose strength were 
assessed in the post-index 6-month period. Persistence was defined as the 
duration of BTDS therapy prior to the 1st28-day refill gap. Descriptive statistics, t-
tests and ANOVA were used to compare differences in persistence across  
patient cohorts. RESULTS: The study included 10,457 patients newly treated with 
BTDS. Medication persistence was significantly higher across patients receiving 
higher final doses (49.1 days (n=3,769), 69.2 days (n=4,463) and 97 days (n=2,225) 
for 5mcg/hr, 10 mcg/hr and 20 mcg/hr doses, respectively, p<0.0001). 
Additionally, persistence for patients who had a dose change (n=3,297) was 111.4 
days, compared to 47.8 days for those who did not (p<0.0001). Sensitivity 
analyses on patients with ≥2 BTDS claims (n=5,444) showed that patients on final 
dose strength 10 mcg/hr and 20 mcg/hr had 8.9 days and 19.2 days longer 
persistence when compared to patients on 5 mcg/hr (p<0.0001). Also, among 
patients with ≥2 BTDS claims, persistence was, on average, 17.1 days longer  
for patients who had a dose change compared to patients who did not (p<0.0001). 
CONCLUSIONS: BTDS persistence was longer among patients with higher final 
dose strengths and who had a dose change. Management of BTDS dosage  




IDENTIFYING POTENTIALLY NON-ADHERENT RHEUMATOLOGY PATIENTS: 
APPLICATION OF THE COMPLIANCE-QUESTIONNAIRE-RHEUMATOLOGY  
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OBJECTIVES: The 19 item Compliance-Questionnaire-Rheumatology (CQR) is an 
open access questionnaire that was developed by Rheumatologists in the 
Netherlands, to predict the potential for non-adherence specifically in 
rheumatology patients. It was validated against gold standard compliance 
measures. The questionnaire item bank came from home and focus group 
patient interviews. Responses are provided on a 4 point Likert scale delineated 
by strength of agreement. METHODS: Patients self-reporting a diagnosis of 
rheumatoid arthritis (RA) and residing in the United States completed a self-
administered, internet-based questionnaire in the Fall of 2011, which included 
the CQR. CQR data were analysed using an automated analytical tool provided by 
the developers. Based on the validation paper, individual raw CQR questions are 
weighted to produce adjusted total summary scores for each patient, which can 
then be compared to validated cutoff values for specified levels of desired 
compliance ranging from 50-95%, to establish whether the patient is or is not 
likely to be non-compliant. Different weights exist depending on whether the 
user is interested in the potential for “dosing” compliance (the percentage of 
days the correct number of doses were taken) or dose “taking” compliance (the 
percentage of prescribed doses taken). RESULTS: Survey respondents were 76.2% 
female, 86.2% Caucasian, with mean age 56.4 years. At the 90%, 80%, and 50% 
minimum thresholds for “dosing” compliance, 99.2%, 83.8% and 66.1% of patients 
were identified as potentially non-compliant respectively. CONCLUSIONS: 
Depending on desired compliance thresholds, at least 60% of self-reported RA 
patients demonstrate attributes identifying them as potentially non-compliant 
with treatment. This instrument may be useful in streaming patients into 
adherence programs, identifying appropriate patients for specific treatments or 
improving patient/physician discourse during shared decision making 
discussions. Future work should look at validating against other common 




HOW COMPLIANCE IS MEASURED IN TRANSPLANT PATIENTS TAKING 
IMMUNOSUPPRESSIVE AGENTS: A SYSTEMATIC LITERATURE REVIEW  
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OBJECTIVES: Non-adherence to medication is one of the biggest issues in health 
care today, where roughly half of all prescriptions for drugs to be taken on  
an ongoing basis are either not completed or are never even filled. Non-
adherence can lead to increased rates of AEs and increased cost of care; thus, 
adherence to medication may impact the effectiveness of a product in the real-
world. This is especially relevant for transplant patients, where the 
consequences of non-adherence can increase the risk of acute rejections. Despite 
this concern, information on transplant patient medication adherence is  
still uncommon, and a standard measure of adherence is not available. Our 
objective was to examine the existing literature to assess what adherence 
measures are implemented and whether they are implemented routinely. 
METHODS: A systematic review of peer-reviewed literature was conducted  
to identify RCTs and observational studies that measured compliance in 
transplant patients taking immunosuppressive agents. We searched Embase and 
Medline for studies from 2008-present in which adherence, compliance, or 
persistence appeared in the title, abstract, or as an index term. RESULTS: The 
search identified 46 studies, of which 11 measured adherence. Methods of 
measuring compliance varied among the included studies, some of which used 
multiple measurements: Basel Assessment of Adherence Scale to 
Immunosuppressives, 2; Medication Event Monitoring System, 2; blood test, 3; 
self-report, 2; VAS, 1; Likert scale, 1; pill counts, 1; questionnaire, 1; continuous 
measures of medication adherence, 1; measure not specified in remaining 
studies. In most studies, the patient, not physicians, assessed their own 
compliance. CONCLUSIONS: Adherence to medication in transplant patients is 
neither measured regularly nor in a consistent manner. All studies of transplant 
patients should assess medication adherence, and further studies must be 
conducted to discern a single reliable and economical measurement of 
compliance in transplant patients.  
